The British Association for the Study of the Liver is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
The British Association for the Study of the Liver aims to disseminate research findings and clinical expertise, to promote opportunities for collaboration in liver research, to provide a voice that can advise and interact with the media and advises policymakers.
Dr Luke Boulter (centre) winner of the BASL Dame Sheila Sherlock Prize Lecture in 2015, he is pictured here with his team David Wilson (left) and Ronan Mellin (right). The Prize Lecture took place this year at the Basic Science Retreat where Dr Boulter was presented with a crystal award and £1,000.
Dr Tom Bird winner of the BASL Andy Burroughs Young Investigator Award 2015. This is a new award given in honour of the late Professor Andrew Burroughs. Dr Bird presented a 30 minute lecture at the BLTG Meeting and was awarded a crystal award and £1,000.
The BASL Annual Meeting is the highlight of the BASL calendar and the main liver meeting in the UK. Join us in Manchester from 7 - 9 September. Participating at our conference provides a unique opportunity to be part of this exciting and vibrant event.
Find out more
Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.
BASL ANNUAL MEETING, BLTG Transplant Meeting & BASLNF Meeting 2016
Manchester Central, 6-9 September
FIND OUT ALL OF THE INFORMATION BY VISITING OUR ANNUAL MEETING WEBSITE - CLICK HERE.
BASL is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.
Members of BASL receive the following benefits:
- discounted registration rates for the annual meeting and other relevant meetings
- eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
- eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.
Click here to find out more about joining us.
A large real world study has shown direct-acting antiviral (DAA)-based therapy is safe and effective in HCV patients with compensated Child-Pugh score (CP) A cirrhosis.
In this multi-national study, at centres in Canada, Germany and the Netherlands, 433 cirrhotic patients with chronic HCV infection started DAA-based treatment.
The SVR12 rate was similar among patients with CP A (85.9%) and CP B/C (82.2%). Baseline albumin <35 g/L (hazard ratio 3.11), baseline MELD score ≥14 (hazard ratio 1.63) and HCV genotype 3 (hazard ratio 2.05) were independently associated with hepatic decompensation during antiviral treatment among patients with CP B/C.
The researchers suggest that, for patients with decompensated (CP B/C) cirrhosis, albumin <35 g/L, MELD-score ≥14 and HCV genotype 3 are important risk factors for hepatic decompensation during DAA-based treatment. Therefore, these patients require close monitoring during antiviral therapy or treatment should be deferred until after transplantation.
Safety and effectiveness of DAA-based therapy in patients with chronic HCV infection and cirrhosis. Maan R, van Tilborg M, Deterding K et al. Clin Gastroenterol Hepatol. 2016 Jul 9 [Epub ahead of print]
Although HEV transfusion transmitted infection (TTI) has been reported in some European countries, a large Danish study found no evidence of it in blood donations.
In the study, by researchers from four university hospitals, samples from 25,637 consenting donors collected during one month in 2015 were screened retrospectively using an individual-donation HEV RNA nucleic acid test with a 95% detection probability of 7.9 IU/mL.
Eleven donations (0.04%) were confirmed as positive for HEV RNA (median HEV RNA level, 13 IU/mL). Two donations were successfully genotyped as HEV-gt-3. Only one donor had a travel history outside Europe. Nine of eleven donors were male, but the gender ratio was non-significant compared with the total donor population.
Seven available recipients tested negative for HEV RNA and anti-HEV immunoglobulin M in follow-up samples. One recipient was HEV RNA-negative but anti-HEV immunoglobulin G-positive. HEV TTI was considered unlikely, but a transfusion-induced secondary immune response could not be excluded. Phylogenetic analysis showed relatively large sequence differences between HEV from donors, symptomatic patients, and swine.
The researchers concluded that despite an HEV RNA prevalence of 0.04% in Danish blood donations, all HEV-positive donations carried low viral loads, and no evidence of TTI was found.
Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors. Harritshøj LH, Holm DK, Saekmose SG et al. Transfusion. 2016 Jul 7 [Epub ahead of print]
New global data show the absolute burden and relative rank of viral hepatitis has increased over the past quarter of a century.
A multi-national team of researchers used data from the Global Burden of Disease (GBD) Study to estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2013.
Global viral hepatitis deaths increased in that period, from 0.89m to 1.45m, and the sum of years lost went from 31m to 41.6m and years lived with disability from 0.65m to 0.87m. Disability-adjusted life-years increased from 31.7m to 42.5m. In 2013, viral hepatitis was the seventh leading cause of death worldwide, compared with tenth in 1990.
The researchers concluded that, unlike most communicable diseases, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013. They suggest the enormous health loss attributable to viral hepatitis, and the availability of effective vaccines and treatments, represents an important opportunity to improve public health.
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Stanaway JD, Flaxman AD, Naghavi M et al. Lancet. 2016 Jul 6 [Epub ahead of print]
This final guideline has now been published on the NICE website.
You can also find the supporting evidence, as well as all the stakeholder comments that we received during consultation and the responses to these comments. The comments were invaluable in helping us to develop and refine the guideline. We have also produced an equality impact assessment to support the guideline.
The recommendations in the guideline have been included in a NICE Pathway, which is an online tool that brings together all related NICE guidance and associated products in a set of interactive, topic-based diagrams. There is a version of the guideline for people using services, carers and the public called 'Information for the public'
If you have any queries, please contact Jill Peacock at email@example.com.
This final guideline has now been published on the NICE website.
You can also find the supporting evidence, as well as all the stakeholder comments that we received during consultation and the responses to these comments.The comments were invaluable in helping NICE to develop and refine the guideline. Nice have also produced an equality impact assessment to support the guideline.
The recommendations in the guideline have been included in a NICE Pathway, which is an online tool that brings together all related NICE guidance and associated products in a set of interactive, topic-based diagrams. There is a version of the guideline for people using services, carers and the public called 'Information for the public'.
If you have any queries, please contact Jill Peacock at firstname.lastname@example.org .
People with HCV appear to be more impulsive and take more risks than individuals with other liver diseases, a new study suggests.
In the study, at Brazil’s Federal University of Bahia, Brazil, 269 adults with liver diseases were divided into a viral group of 157 patients with HCV and a non-viral group of 112. Risk behaviours were evaluated by a socio-demographic questionnaire. Impulsivity was assessed through Barratt Impulsiveness Scale (BIS-11). Psychiatric comorbidities were investigated by the Mini International Neuropsychiatric Interview 5.0.0.
The viral group patients had higher impulsivity than the non-viral group in all domains: attentional impulsivity, motor impulsivity, and non-planning. Risk behaviours were also shown to be associated with impulsivity levels. The results suggest that HCV-infected patients are more impulsive than individuals with other liver diseases, even when analyses are controlled for the presence of comorbid mental disorders. In addition, at-risk behavior was significantly mediated by impulsivity.
Risk-taking behavior and impulsivity among HCV-infected patients. Dantas-Duarte A, Morais-de-Jesus M, Nunes AP et al. Psychiatry Res. 2016 Jun 22; 243:75-80 [Epub ahead of print]
Collaborative care modestly improved depression among patients treated at chronic HCV clinics, a new study found
Collaborative care models have been shown to improve depression outcomes in primary care settings. The new study was conducted at four chronic HCV clinics in US Veterans Affairs facilities by a collaborative depression care team consisting of a depression care manager, pharmacist and psychiatrist.
Baseline screening identified 263 HCV-infected patients with depression. In unadjusted analyses, intervention participants' reports trended toward more treatment response (19% versus 13%) and remission (12% versus 6%), but total number of depression-free days (50.9) was similar to that of usual care participants (50.7).
These trends did not reach statistical significance for the overall sample in the adjusted analyses: response (odds ratio 2.02), remission (odds ratio 2.63), and depression-free days (7.6). However, the intervention was effective in improving all three outcomes for patients who did not meet criteria for remission at baseline.
Collaborative care for depression in chronic hepatitis C clinics. Kanwal F, Pyne JM, Tavakoli-Tabasi S et al. Psychiatr Serv. 2016 Jul 1 [Epub ahead of print]
A new article reviews the significance of HBV infection and the vaccination and screening measures needed to achieve immunity in children receiving liver transplants.
The review found HBV non-immunity among transplant candidates is higher than expected, even after appropriate completion of the vaccine series. Annual measurement of quantifiable HBV surface antibody in this vulnerable group should guide administration of booster and/or re-vaccination, thus improving immunoprotection.
The authors point out the liver plays a vital role in immune regulation. It induces immune tolerance and competence, and both clears antigens from the circulation and generates liver-primed memory cells through antigen presentation via hepatic scavenger cells. Lymphocyte populations are depleted in patients with liver disease.
The reviewers summarise immunity provided during early childhood against HBV infection is important to both paediatric liver transplant candidates and aging recipients. The field of paediatric transplantation is ripe for further functional cellular and humoral immunity studies on childhood HBV vaccines.
Hepatitis B immunity in the pediatric liver transplant population. Patel SS, Leung DH. Curr Opin Pediatr. 2016 Jun 29 [Epub ahead of print]
Venue: The Royal Free Hospital, London
This is the 2nd in a series of International meetings with the Sheila Sherlock brand aimed at renovating the tradition of the periodic updates introduced by Dame Sheila Sherlock at the Royal Free Hospital. This new series is dedicated to current fundamental themes in Hepatology that will be presented and discussed by the Royal Free Liver Specialists together with some of the most renown International speakers.
Full programme information can be downloaded here - Download Programme 1-3 Sept 2016.pdf .
To find out more information and how to Register for the event click > here.
Please contact Lynn Knight if you have any questions - email@example.com.
Venue: Manchester Central, Manchester
The BASL BLTG School of Transplantation offers an excellent platform for trainees with lectures delivered by carefully selected leading speakers from the UK. The topics covered include liver transplant, acute liver failure, surgical aspects of liver transplantation and post-transplant management.
The programme compliments the BASL British Liver Transplant Group (BLTG) Meeting, which is taking place at the same venue on 6th & 7th September (a.m.), with great opportunities for interaction.
Delegates will be encouraged to attend this day along with the BLTG themed sessions on the morning of Wednesday 7th September before the BASL Annual Meeting which starts on the afternoon of Wednesday 7th September.
Please click here to view the 'draft' programme Download Draft Transplant School 2016_Programme Published.pdf
To book for the event click > here.
Venue - Manchester Central
The Chair of the BLTG, Professor Darius Mirza would like to invite you to the third meeting of the BLTG (British Liver Transplant Group).
As an affiliate of BASL, the BTLG has built on the role of the UK and Ireland Annual Meeting and will integrate the meetings previously organised by each individual transplant centre to offer a central stage for those operating in or with a strong interest in the field of liver transplantation.
This meeting will be linked to the BLTG Sessions and Williams-Calne Lecture within the BASL Annual Meeting programme on Wednesday 7th September; 08.30-13.00.
We hope that you will be present at this meeting, which will be attended by both eminent UK and international speakers, including Professor Mike Lucey, University of Wisconsin School of Medicine and Public Health, who will also deliver the distinguished Williams-Calne lecture.
REGISTRATION - all of the details including the programme can be found on the BASL / BLTG Annual Meeting website by clicking > here.
Andy Burroughs Young Investigator Award - submit your application for the Andy Burroughs Young Investigator Award - deadline 9:00 Monday 8th August - read more on the BASL / BLTG Annual Meeting website > here.
Registration is now OPEN
Venue: Manchester Central, Manchester
VISIT THE BASL Annual Meeting 2016 website to find out Programme Information, to Submit an Abstract and to Register - CLICK HERE.
The BASL Annual Meeting is the highlight of the BASL calendar and the main liver meeting in the UK. This year we hope to attract in excess of 500 delegates, bringing together clinicians, nurses, scientists and all those interested in liver disease.
Eminent UK and overseas speakers converge to deliver an informative and exciting meeting over three days, which for September 2016 will take place at Manchester Central.
ABSTRACTS - now closed.
A preview of the programme can also be found here Download Annual Meeting Programme.pdf
This symposium is the leading International conference focused on the management of hepatitis among substance users. It is organised by the International Network for Hepatitis in Substance Users (INHSU). In 2015, INHSU decided to move to an annual symposium to keep pace with the rapid development of new therapies and exciting new research on HCV care among people who inject drugs. Hence, the 2016 INHSU symposium will be held in Oslo, Norway.
The International Symposium on Hepatitis in Substance Users attracts delegates including health professionals (doctors, nurses and allied health), researchers, community organisations, people who use drugs and policy makers.
Abstract submission is now open. Submit your abstract before Friday 22 April 2016.
For further information and to register click here.
Coimbra Liver Transplantation Conference - Coagulation Liver Disease and Liver Transplant Facts and Controversies
Event Content - Monothematic meeting will cover a variety of concepts in liver and coagulation, highlighting management before, during and after liver transplant.
Venue - Coimbra Paediatric Hospital Auditorium - Coimbra Hospital and University Centre
To find out more information click here.
The Royal College of Physicians of Edinburgh (RCPE) and the Society for Acute Medicine (SAM) are delighted to be bringing you the most ambitious international programme on the past, present and future of medicine. This two-day conference will combine the historical aspects of medicine with a look to the future for healthcare across a broad range of clinical topics.
Venue: The Edinburgh International Conference Centre
Abstracts: Deadline 10 July 2016
For further information view here Download Edinburgh International Conference of Medicine Past Present and Future.pdf
You will be able to design your own agenda for the conference, choosing from a comprehensive range of over 35 parallel sessions covering over 15 specialties, ranging from acute medicine, cardiology, care of the older patient, diabetes, neurology and respiratory to health & wellbeing, maternal medicine and patient involvement.
This conference is open to all healthcare professionals at all stages of their careers and is a great opportunity to keep up to date with the latest clinical research, opinions and innovations in medicine, as well as building your network.
The conference has been approved for 12 CPD points.
Full details on abstract submission, registration and programme are available by clicking here.
You are invited to the APASL Single Topic Conference on Non-responders that will be held between 22nd – 24th September, 2016 at the Hilton Bosphorus Hotel, Istanbul, Turkey.
To find out full information about the conference visit the website > here.
Important deadlines to note are as follows:
Early Bird Registration deadline - 1 July 2016
Abstract deadline - 29 July 2016
Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.
Ward membership benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September.
To find out how to apply click here
NURSES TRAVEL BURSARY 2016 - additional places available.
We are delighted to announce that AbbVie UK Ltd is offering 30 bursaries to support nurses attending the BASL Annual Meeting 2016.
Due to not all of the bursary places being filled in the first round, we are inviting applications for the final 9 places.
The bursary application deadline is Monday 1st August 2016. Find out how to apply > here.
The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account